Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 2/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25259821 | 1.00 | PSMB1 (0.49) | PSMB1PSMB5PSMB2CAPN1CTSB | |
| SCHEMBL30450002 | 1.00 | PSMB1 (0.49) | PSMB1PSMB5PSMB2CAPN1CTSB | |
| Carbamic Acid SCHEMBL30450803 | 0.97 | CAPN1 (0.48) | PSMB1PSMB5PSMB2CAPN1CTSB | |
| SCHEMBL5712419 | 0.94 | CAPN1 (0.54) | PSMB1PSMB5PSMB2CAPN1CTSB | |
| SCHEMBL5712422 | 0.87 | CTSB (0.61) | PSMB1PSMB5PSMB2CAPN1CTSB | |
| SCHEMBL4968073 | 0.85 | MME (0.59) | CTSLMMP1MMP3MMEMMP9 | |
| SCHEMBL3362027 | 0.81 | CAPN1 (0.46) | PSMB1PSMB5PSMB2CAPN1CTSB | |
| SCHEMBL2246262 | 0.81 | MME (0.47) | PSMB1PSMB5PSMB2CTSLMMP1 | |
| SCHEMBL3368130 | 0.81 | ALDH1A1 (0.43) | PSMB1PSMB5PSMB2CTSLMMP1 | |
| SCHEMBL20741008 | 0.80 | CTSK (0.48) | CTSLMMP1MMP3ALDH1A1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250702-A1 | Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments | RECHARGE B.V. (NL) | 2005-11-10 | — | — | US | claimed |
| EP-1062243-A2 | CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS | Universiteit Utrecht (NL) | 2000-12-27 | — | — | EP | claimed |
| EP-0943624-A1 | Peptidic inhibitors of down-regulation of growth hormone receptor | Universiteit Utrecht (NL) | 1999-09-22 | — | — | EP | claimed |
| WO-1999046298-A2 | CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS | UNIVERSITEIT UTRECHT (NL) | 1999-09-16 | — | — | WO | claimed |
| WO-2023101457-A1 | COMPOSITION FOR PREVENTING OR TREATING BILIARY TRACT CANCER | 연세대학교 산학협력단 | 2023-06-08 | — | — | WO | disclosed |
| US-20150320754-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20050250702-A1 | Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments | RECHARGE B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
| US-6855546-B1 | Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments | UNIVERSITEIT UTRECHT (NL) | 2005-02-15 | — | — | US | disclosed |
| EP-0927249-B1 | E2F UBIQUITINATION DOMAIN, AND ASSAYS FOR INHIBITORS OF E2F UBIQUITINATION | TOPOTARGET UK LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6368809-B1 | A DETECTION METHOD FOR A TRANSCRIPTION FACTOR UBIQUITIN-MEDIATED DEGREDATION INHIBITOR BY MIXING A POLYPEPTIDE WITH A POTENTIAL INHIBITOR AND DETERMINING THE LEVEL OF REDUCED UBIQUINATION OF THE POLYPEPTIDE | PROLIFIX LIMITED (GB) | 2002-04-09 | — | — | US | disclosed |
| WO-2001081427-A1 | A REPORTER PROTEIN CONSTRUCT, PARTLY COMPRISING GPF | KAROLINSKA INNOVATIONS AB (SE) | 2001-11-01 | — | — | WO | disclosed |
| EP-1062243-A2 | CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS | Universiteit Utrecht (NL) | 2000-12-27 | — | — | EP | disclosed |
| EP-0943624-A1 | Peptidic inhibitors of down-regulation of growth hormone receptor | Universiteit Utrecht (NL) | 1999-09-22 | — | — | EP | disclosed |
| WO-1999046298-A2 | CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS | UNIVERSITEIT UTRECHT (NL) | 1999-09-16 | — | — | WO | disclosed |
| EP-0927249-A1 | E2F UBIQUITINATION DOMAIN, AND ASSAYS FOR INHIBITORS OF E2F UBIQUITINATION | Vereniging Het Nederlands Kanker Instituut (NL) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998007852-A1 | E2F UBIQUITINATION DOMAIN, AND ASSAYS FOR INHIBITORS OF E2F UBIQUITINATION | VERENIGING HET NEDERLANDS KANKER INSTITUUT (NL) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997032605-A1 | CYTOMEGALOVIRUS NUCLEIC ACIDS ENCODING PROTEINS HAVING NORMAL OR ALTERED CLASS I MHC BINDING AND TREATMENT OF DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320754-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PSMB1 183/4885PSMB5 198/4885PSMB2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.